Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF

F Romerio, M N Gabriel, D M Margolis, F Romerio, M N Gabriel, D M Margolis

Abstract

A subpopulation of stably infected CD4+ cells capable of producing virus upon stimulation has been identified in human immunodeficiency virus (HIV)-positive individuals (T.-W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano, Nat. Med. 1:1284-1290, 1995). Few host factors that directly limit HIV-1 transcription and could support this state of nonproductive HIV-1 infection have been described. YY1, a widely distributed human transcription factor, is known to inhibit HIV-1 long terminal repeat (LTR) transcription and virus production. LSF (also known as LBP-1, UBP, and CP-2) has been shown to repress LTR transcription in vitro, but transient expression of LSF has no effect on LTR activity in vivo. We report that both YY1 and LSF participate in the formation of a complex that recognizes the initiation region of the HIV-1 LTR. Further, we have found that these factors cooperate in the repression of LTR expression and viral replication. This cooperative function may account for the divergent effects of LSF previously observed in vitro and in vivo. Thus, the cooperation of two general cellular transcription factors may allow for the selective downregulation of HIV transcription. Through this mechanism of gene regulation, YY1 and LSF could contribute to the establishment and maintenance of a population of cells stably but nonproductively infected with HIV-1.

References

    1. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5706-10
    1. Mol Cell Biol. 1997 Jul;17(7):3786-98
    1. J Virol. 1986 Aug;59(2):284-91
    1. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9759-63
    1. EMBO J. 1987 Dec 1;6(12):3761-70
    1. Genes Dev. 1988 Sep;2(9):1101-14
    1. Methods Enzymol. 1990;182:194-203
    1. Genes Dev. 1990 Feb;4(2):287-98
    1. Science. 1991 Mar 22;251(5000):1476-9
    1. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2726-30
    1. Cell. 1991 Oct 18;67(2):377-88
    1. Mol Cell Biol. 1992 Feb;12(2):828-35
    1. Methods Enzymol. 1991;208:10-23
    1. Mol Cell Biol. 1993 Feb;13(2):1251-63
    1. EMBO J. 1993 Feb;12(2):501-11
    1. J Biol Chem. 1993 Mar 25;268(9):6714-20
    1. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6145-9
    1. J Virol. 1994 Feb;68(2):905-10
    1. Mol Cell Biol. 1994 Mar;14(3):1776-85
    1. J Biol Chem. 1994 Aug 19;269(33):21269-76
    1. J Virol. 1995 Jan;69(1):1-12
    1. Science. 1995 Jan 27;267(5197):531-6
    1. J Virol. 1995 Jun;69(6):3584-96
    1. J Virol. 1995 Jul;69(7):4323-30
    1. Nat Med. 1995 Dec;1(12):1284-90
    1. J Virol. 1996 Nov;70(11):7695-705
    1. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12845-50
    1. Genes Dev. 1997 Jan 1;11(1):1-10
    1. Cell. 1997 May 2;89(3):325-8

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir